Mersana, a privately held, venture-backed company, is developing novel oncology agents based on clinically validated compounds through the use of Fleximer®, a proprietary bio-degradable and bio-inert material that enhances the pharmacokinetics, safety, and solubility of drugs. Mersana has an exclusive license from the Massachusetts General Hospital for its core technologies. Mersana's pipeline includes compounds with activity against multiple tumor types and human proof-of-concept that are improved by its proprietary technologies.